Wall Street Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Wall Street Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-5,260	Closed	-$650K	–	345
2015 Q2	$650K	Sell	5,260 -300	-5%	-$37.8K	0.06%	249
2015 Q1	$656K	Hold	5,560	–	–	0.06%	249
2014 Q4	$661K	Hold	5,560	–	–	0.06%	231
2014 Q3	$624K	Buy	5,560 +853	+18%	+$81.2K	0.06%	233
2014 Q2	$446K	Sell	4,707 -820	-15%	-$57.5K	0.04%	269
2014 Q1	$391K	Hold	5,527	–	–	0.03%	284
2013 Q4	$411K	Sell	5,527 -60	-1%	-$4.18K	0.03%	283
2013 Q3	$424K	Sell	5,587 -4,887	-47%	-$389K	0.04%	271
2013 Q2	$839K	Buy	+10,474	New	+$771K	0.09%	200

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wall Street Associates's VRTX Position: Q3 2015 in Review

Wall Street Associates sold out of Vertex Pharmaceuticals (VRTX) in Q3 2015, closing a stake of 5,260 shares — an estimated $650K sold.

Wall Street Associates first reported a position in VRTX in Q2 2013 and held it in 9 quarters. The position peaked at $839K in Q2 2013. 494 funds tracked by Wall St. Rank hold VRTX as of Q3 2015.

Wall Street Associates reported no remaining Vertex Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Wall Street Associates sold 5,260 Vertex Pharmaceuticals shares in Q3 2015, an estimated $650K.
Wall Street Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Wall Street Associates's Vertex Pharmaceuticals position peaked at $839K in Q2 2013.
494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2015.

Based on Wall Street Associates's 13F filing for Q3 2015, filed 12 Nov 2015.